Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Galera Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10596
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Galera Therapeutics Inc (Galera Therapeutics) is a clinical-stage biotechnology company that discovers and develops novel cancer treatments. The company also concentrates on the prevention of radiation-induced toxicity including mucositis and the treatment of cancer. Its GC4419 is a selective small molecule superoxide dismutase enzyme mimetic that quickly converts superoxide free radical molecules to hydrogen peroxide and oxygen. Galera Therapeutic’s dismutase mimetics copies the human superoxide dismutase enzyme activities and overcome the deficiency. The company’s research and development unit concentrates on protection from normal tissue damage and direct anti-cancer therapy. Galera Therapeutics is headquartered in Malvern, Pennsylvania, the US.

Galera Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Asset Transactions 17
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc – Key Competitors 18
Galera Therapeutics Inc – Key Employees 19
Galera Therapeutics Inc – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Product Approvals 21
Jul 31, 2017: Galera Therapeutics Announces Promising Innovative Medicines Designation from the United Kingdom’s Medicines and Healthcare Products Regulatory Agency for GC4419 for the Reduction of Oral Mucositis in Head and Neck Cancer Patients 21
Clinical Trials 22
Jan 04, 2018: Data from Galera Therapeutics’ 223-Patient Phase 2b Clinical Trial of GC4419 to be Presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium 22
Dec 18, 2017: Galera Therapeutics Reports Statistically Significant Results in a 223-Patient Phase 2b Trial of GC4419 for Severe Oral Mucositis in Patients with Head and Neck Cancer 23
Jun 15, 2017: Galera Therapeutics Completes Enrollment in Phase 2b Clinical Trial with Lead Compound GC4419 for Treatment of Oral Mucositis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Galera Therapeutics Raises USD70 Million in Series C Venture Financing 10
Galera Therapeutics Raises Additional USD15 Million in Series B Financing 12
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 13
Galera Therapeutics Raises USD37 Million in Series B Financing 14
Galera Therapeutics Raises USD4.74 Million In Venture Financing 15
Galera Therapeutics Raises US$11 Million In Series A Financing 16
Galera Therapeutics Enters into Royalty Agreement with Clarus Ventures 17
Galera Therapeutics Inc, Key Competitors 18
Galera Therapeutics Inc, Key Employees 19

List of Figures
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Galera Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Galera Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hays plc (HAS):企業の財務・戦略的SWOT分析
    Hays plc (HAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Custodian & Allied Plc:企業の戦略・SWOT・財務分析
    Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report Summary Custodian & Allied Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Industrias Nucleares do Brasil S.A.:企業の戦略的SWOT分析
    Industrias Nucleares do Brasil S.A. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Koninklijke Vopak NV (VPK):石油・ガス:M&Aディール及び事業提携情報
    Summary Koninklijke Vopak NV (Vopak) is an independent tank storage company that stores and handles liquid oil products, chemicals, vegetable oils, biofuels and liquefied natural gases. It also offers logistics services, handles customs formalities and documentation for its customers at its terminal …
  • Western & Southern Financial Group, Inc.:企業の戦略・SWOT・財務情報
    Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Western & Southern Financial Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Faes Farma SA (FAE):企業の財務・戦略的SWOT分析
    Faes Farma SA (FAE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Impala Platinum Holdings Ltd:戦略・SWOT・企業財務分析
    Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Impala Platinum Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • J B Chemicals and Pharmaceuticals Ltd (JBCHEPHARM):企業の財務・戦略的SWOT分析
    Summary J B Chemicals and Pharmaceuticals Ltd (JBCPL) is a pharmaceutical company that manufactures and markets pharmaceutical formulations. The company provides products such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, capsules, and others. It provides contract …
  • Quorum Business Solutions Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Quorum Business Solutions Inc (QBS) is a technology company that develops, implements, and supports software solutions. The company offers software in the areas of accounting; transactions and logistics management; land, property and right of way management; liquid and gas measurement; energ …
  • PNE Wind AG (PNE3):電力:M&Aディール及び事業提携情報
    Summary PNE Wind AG (PNE) is a renewable energy company, which develops onshore and offshore wind farms. It has a presence in the wind energy value chain, from site exploration and implementation of approval procedure, financing and turnkey construction to operation and repowering. The company also …
  • Komax Holding AG (KOMN):企業の財務・戦略的SWOT分析
    Komax Holding AG (KOMN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • CNP Assurances SA:企業のM&A・事業提携・投資動向
    CNP Assurances SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CNP Assurances SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Northwestern University:企業のM&A・事業提携・投資動向
    Northwestern University - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Northwestern University Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Hydra Biosciences Inc-製薬・医療分野:企業M&A・提携分析
    Summary Hydra Biosciences Inc (Hydra) is a biopharmaceutical company that develops novel drugs. The company’s pipeline candidate HX-100 is developed to treat diabetic neuropathy and allergic asthma. It offers other drugs for the therapeutic areas including inflammation, pain, renal, anxiety and pulm …
  • Compagnie Des Alpes Sa
    Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report Summary Compagnie Des Alpes Sa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • PGE Polska Grupa Energetyczna SA (PGE):企業の財務・戦略的SWOT分析
    PGE Polska Grupa Energetyczna SA (PGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Curetis NV (CURE):医療機器:M&Aディール及び事業提携情報
    Summary Curetis NV (Curetis) is a medical device company that offers molecular diagnosis solutions. The company provides diagnostic systems developed with Unyvero platform for severe infectious diseases. Its products are used in rapid diagnosis for cartridges, diseases such as implant and tissue inf …
  • ENERQOS SpA:電力:M&Aディール及び事業提携情報
    Summary Enerqos SpA (Enerqos), a subsidiary of Climate Change Capital Private Equity LP, is an energy service company that offer solutions to improve energy efficiency. The company operates in the planning, management, financing and monitoring of projects in the renewable energy sector. It implement …
  • Vivakor Inc (VIVK):企業の財務・戦略的SWOT分析
    Summary Vivakor Inc (Vivakor) is a technology and asset acquisition company that creates, acquires and accumulates distinct assets, intellectual properties, and various technologies. The company concentrates on precious metals extraction in the US. It also concentrates on oil extraction from shallow …
  • Discovery Holdings Limited (DSY):企業の財務・戦略的SWOT分析
    Discovery Holdings Limited (DSY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆